Core Viewpoint - The demand for cerebrovascular interventional devices in China is increasing due to the rising incidence of cerebrovascular diseases, which are among the top three causes of death in the country, with stroke being the leading cause [1][10]. Industry Definition and Classification - Cerebrovascular diseases are conditions affecting blood vessels in the brain, primarily including ischemic and hemorrhagic strokes. Cerebrovascular interventional surgery involves minimally invasive techniques for diagnosing and treating these conditions [2]. - Cerebrovascular interventional devices include medical consumables required for these surgeries, such as embolization coils, thrombectomy stents, and aspiration catheters [2]. Industry Characteristics - The cerebrovascular interventional device industry is characterized by high technical barriers, continuous technological innovation, and favorable industry policies [4]. Current Industry Status Global Market - The global market for cerebrovascular interventional devices is projected to reach USD 3.292 billion in 2024, with North America accounting for 43.04% of the market, Europe 26.56%, and Asia-Pacific 25.27%. The market is expected to grow to USD 3.974 billion by 2025 [7]. Chinese Market - In China, the market for cerebrovascular interventional devices is expected to reach CNY 3.504 billion in 2024, with specific segments such as intracranial thrombectomy stents at CNY 1.584 billion and aspiration catheters at CNY 0.272 billion. By 2025, the market is projected to grow to CNY 4.879 billion [10][13]. Industry Supply Chain - The upstream of the cerebrovascular interventional device industry consists of raw material suppliers, including tubing and alloy materials. The midstream includes manufacturers like Medtronic and Johnson & Johnson, while the downstream consists of distribution channels and end customers, primarily medical institutions [15].

证券日报网讯12月16日，赛诺医疗在互动平台回答投资者提问时表示，根据公司最近一次已披露的《赛 诺医疗2025年第三季度报告》，截至2025年9月30日，公司股东人数为29360户。 ...

证券日报网讯 12月16日晚间，赛诺医疗发布公告称，公司2025年第一次临时股东大会审议通过《赛诺 医疗科学技术股份有限公司关于增加注册资本并修改的议案》《赛诺医疗科学技术股份有限公司关于取 消监事会暨废止的议案》《赛诺医疗科学技术股份有限公司关于外部（非独立）董事津贴标准的议案》 等多项议案。 （编辑 任世碧） ...

（编辑 任世碧） 证券日报网讯 12月16日晚间，赛诺医疗发布公告称，公司于2025年12月16日上午在公司会议室召开赛 诺医疗科学技术股份有限公司2025年第一次职工代表大会，审议通过"赛诺医疗科学技术股份有限公司 关于选举第三届董事会职工董事的议案"，选举陈琳女士为公司第三届董事会职工董事。 ...

2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 证券代码：688108 证券简称：赛诺医疗 公告编号：2025-064 赛诺医疗科学技术股份有限公司 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权 数量的情况： | 1、出席会议的股东和代理人人数 | 183 | | --- | --- | | 普通股股东人数 | 183 | | 2、出席会议的股东所持有的表决权数量 | 103,715,326 | | 普通股股东所持有表决权数量 | 103,715,326 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 24.9286 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 24.9286 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东大会主持情况等。 本次股东大会由公司董事会召集，董事长孙箭华先生主持召开。本次股东大会采用现场投 票和网络投票相结合的方 ...

& 所 法律意见书 上海市锦天城（北京）律师事务所 关于赛诺医疗科学技术股份有限公司 2025 年第一次临时股东大会之 法 律 意 见 书 法律意见书 上海市锦天城（北京）律师事务所 关于赛诺医疗科学技术股份有限公司 2025 年第一次临时股东大会之 法律意见书 致:赛诺医疗科学技术股份有限公司 根据《中华人民共和国证券法》(以下简称"《证券法》")、《中华人民共 和国公司法》(以下简称"《公司法》")和中国证券监督管理委员会《上市公司 股东会规则》(以下简称"《股东会规则》")等法律、行政法规、规章和规范性 文件的要求以及《赛诺医疗科学技术股份有限公司章程》(以下简称"《公司章程》"), 上海市锦天城(北京)律师事务所(以下简称"本所")接受赛诺医疗科学技术股 份有限公司(以下简称"公司")委托,指派本所律师于2025年12月16日出席公司 2025年第一次临时股东大会(以下简称"本次股东大会"),并就本次股东大会相 关事项出具本法律意见书。 为出具本法律意见书之目的,公司已向本所提供了与本次股东大会召开事宜有 关的文件资料。公司承诺其所提供给本所的文件资料或所作的陈述和说明是真实、 准确、完整的,并无隐瞒 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-063 陈琳女士持有公司股份 126,000 股，与公司控股股东、实际控制人、持股 5%以上 股东及其他董事、监事、高级管理人员无关联关系；不存在《公司法》第一百四十六 条规定的情形；未被中国证监会采取证券市场禁入措施；未被证券交易所公开认定为 不适合担任上市公司董事、监事和高级管理人员；未受过中国证监会行政处罚和证券 交易所公开谴责或通报批评；没有因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规 被中国证监会立案调查等情形；经查询不属于"失信被执行人"。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2025 年 12 月 16 日上午在公司会议室召开赛诺医疗科学技术股份有限公司 2025 年第一次职工 代表大会，审议通过"赛诺医疗科学技术股份有限公司关于选举第三届董事会职工董 事的议案"，选举陈琳女士为公司第三届董事会职工董事，上述职工董事简历详见附 件。 该职工董事将与公司股东大会选举的第三届董事会其他董事一起，共同组成公司 第三届董事会，任期与第三届董事会届期相同。 特此公告。 赛诺医疗科学技术股份有限公司董事会 2025 ...

Core Viewpoint - The demand for neurointerventional medical devices in China is increasing due to the rising incidence of cerebrovascular diseases, with stroke being the leading cause of death among Chinese residents. The market for neurointerventional consumables is projected to grow significantly in the coming years [1][5]. Industry Definition and Classification - Neurointerventional devices are medical consumables required for neurointerventional surgeries, primarily used to diagnose and treat cerebrovascular diseases through minimally invasive techniques [2][3]. Industry Development Status - The global market for neurointerventional consumables is expected to reach $3.292 billion in 2024, with North America holding a 43.04% market share. The Chinese market for these consumables is projected to grow from 3.504 billion yuan in 2024 to 4.879 billion yuan in 2025 [5][6]. Industry Chain - The upstream of the neurointerventional device industry consists of raw material suppliers, while the midstream includes manufacturers like Medtronic and Johnson & Johnson. The downstream consists of medical institutions that utilize these devices [7]. Industry Development History - The neurointerventional device industry in China has evolved through three stages: the embryonic stage (1980-1999), the initiation stage (2000-2010), and the rapid development stage (2011-present) [8]. Competitive Landscape - The market is primarily dominated by multinational companies such as Medtronic and Johnson & Johnson, while domestic companies like Guichuang Tongqiao and Micron Brain Science are gaining ground through competitive pricing and localized channels [9][10]. Key Enterprises - The leading companies in the Chinese neurointerventional market include Medtronic, Stryker, and Johnson & Johnson, with a significant presence of domestic players like Guichuang Tongqiao and Micron Brain Science [10][11]. Technological Breakthroughs - Domestic companies are achieving technological advancements in core products, allowing them to compete more effectively with international standards while benefiting from cost advantages [12]. Application Scenario Expansion - The application of new technologies such as AI-assisted navigation systems and biodegradable materials is expected to enhance the efficiency and scope of neurointerventional procedures, supported by favorable government policies [13].

证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2025 年第一次临时股东大会 会议材料 2025 年 12 月 赛诺医疗科学技术股份有限公司 2025 年第一次临时股东大会 会议资料 赛诺医疗科学技术股份有限公司 2025 年第一次临时股东大会会议须知 为保障赛诺医疗科学技术股份有限公司（以下简称"公司"）全体股东的合法权益，维护 股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如期、顺利召开，根据《中 华人民共和国公司法》《赛诺医疗科学技术股份有限公司章程》《赛诺医疗科学技术股份有限公 司股东大会议事规则》及中国证监会、上海证券交易所的有关规定，特制定本须知。 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东及股东代理人的合法权益， 除出席会议的股东及股东代理人、公司董事、监事、高级管理人员、见证律师及董事会邀请的 人员外，公司有权依法拒绝其他人员进入会场。 三、出席现场会议的股东及股东代理人须在会议召开前半小时到达会议现场办理签到手续， 并请按规定出示证券账户卡、身份证明文件或营业执照/注册 ...

Summary of Conference Call Records Industry Overview - The medical device industry is experiencing overall performance pressure in 2025, but third-quarter revenues have shown a year-on-year increase, with a narrowing decline in net profit attributable to the parent company, primarily due to domestic medical insurance cost control and geopolitical influences. It is expected that normal growth rates will resume in 2026 [1][3][8]. Key Points on Medical Device Sector - **Domestic Market Dynamics**: The slowdown in hospital bidding in 2024 is impacting revenue realization, with an expected boost from the "old-for-new" policy by the end of 2025. The In Vitro Diagnostics (IVD) sector is under pressure due to centralized procurement price adjustments and tax reimbursements [1][4]. - **International Market Challenges**: Companies are strengthening their overseas presence, but initial high costs are pressuring short-term profits. The impact of US-China tariffs on low-value consumables is significant, with expectations of price recovery in the glove industry from late 2025 to 2026 after inventory digestion [1][4][11]. - **Performance Metrics**: In the first three quarters of 2025, the medical device sector reported revenues of 145.7 billion yuan, a year-on-year decline of 2.4%, and a net profit of 26.5 billion yuan, down 14.4%. However, the third quarter showed a positive revenue trend and a narrowing profit decline [3][15]. Specific Sector Insights - **IVD Sector**: The IVD sector saw a year-on-year decline of 14.5% in the first three quarters, but the third quarter showed improvement with revenues of 11.02 billion yuan, benefiting from the implementation of centralized procurement and the release of DRG/DIP 2.0 [16]. - **High-Value Consumables**: This segment experienced a revenue growth of 6.6% year-on-year, with orthopedics showing a significant growth rate of 18.7%. The recovery in cardiovascular surgeries is driving sales, and the ophthalmology sector presents potential due to low penetration rates [17]. - **Medical Equipment**: The medical equipment sector's revenue remained flat, but profit growth was slightly higher. The imaging equipment sector is benefiting from the "old-for-new" projects, with a notable recovery in the endoscope segment [15]. Vaccine Sector Performance - The vaccine sector faced significant pressure, with revenues declining nearly 50% and profits turning negative. However, there is a quarter-on-quarter improvement trend. Future focus includes the recovery of traditional vaccines and the launch of new pipeline products, such as the domestically produced nine-valent HPV vaccine [2][23]. Life Sciences Upstream Sector - The life sciences upstream sector's performance remained stable, with a year-on-year profit growth of 68% in the third quarter, driven by recovering terminal demand and improved gross margins. The sector is benefiting from the expansion of the biopharmaceutical market and policy support [24]. Regulatory Environment and Challenges - The current regulatory environment emphasizes innovation while ensuring safety and efficacy. Domestic companies face challenges in international certifications, particularly with the FDA and CE, due to quality control issues [20][21][22]. Future Outlook - The industry outlook for 2026 includes a focus on self-sufficiency, innovative devices, and accelerated realization of centralized procurement categories. The recovery of orthopedic products is already evident, and international expansion remains a key area of interest [5][7][19].